Opinion
Video
Biomarkers for Dosing Multiple Sclerosis Therapies
Author(s):
Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, discuss the need for biomarkers that can help guide the optimal dosing for the use of anti-CD20 therapies in a precision fashion.
This is a video synopsis/summary of a panel discussion involving Ahmed Obeidat, MD, PhD; Riley Bove, MD; Stephen Krieger, MD; and Erin Longbrake, MD, PhD.
The conversation revolves around the response of healthcare providers to the COVID-19 pandemic regarding the dosing of NTCD-20 therapies in patients with multiple sclerosis (MS). Many clinicians faced uncertainty regarding whether to extend dosing intervals or continue with standard dosing protocols. However, emerging literature suggests that outcomes for patients on extended dosing intervals are comparable to those on standard schedules.
The speaker emphasizes the variability among patients in their response to treatment and metabolic differences, highlighting the need for individualized dosing strategies. Despite initial concerns about the impact of the pandemic on patients with MS, overall, they have fared well both in terms of infectious outcomes and disease stability.
The discussion underscores the heterogeneity of MS and the necessity for personalized medicine approaches. The speaker discusses the potential for biomarkers or immunological markers to guide dosing decisions in the future, though implementing such a strategy would require a significant paradigm shift in clinical practice.
Ultimately, the conversation emphasizes the importance of advancing personalized medicine in MS treatment to better tailor therapies to individual patient needs, similar to advancements seen in oncology. This shift towards personalized medicine represents an important goal for improving outcomes in MS care.
Video synopsis is AI-generated and reviewed by NeurologyLive editorial staff.
